Technology Platform

Leveraging four core advantages and in-house underlying technologies, we strengthen the foundation for R&D and translation, powering the landing of innovations.

Technology Platform

Leveraging four core advantages and in-house underlying technologies, we strengthen the foundation for R&D and translation, powering the landing of innovations.

Leveraging four core advantages and in-house underlying technologies, we strengthen the foundation for R&D and translation, powering the landing of innovations.

4th GEN SMART ADC

Synergistic targets combination (Coverage and depth of response)

Optimal ADC internalization, release and endosomal escape

Wide payload potency range (>2 magnitudes)

Translational excellence to bridge the pre-clinical to clinical validation

Superior ADC drug-like properties: thermal & PK stability, homogeneity and manufacturability

Seamless PD and CMC execution by MNC veterans

Core Technology Platforms

Zent-iDC™

  • Target-directed ADC delivery to inflamed disease tissues
  • Precise regulations of disease-causing inflammation effectors
  • Orchestrate holistic regulation and control of pathogenic factors
  • Tackling unmet medical needs with novel modalities
  • Synergistic combo opportunities with existing therapies

Gemini-TDC™

  • Rational combination of TAAs with synergistic and complementary MOAs
  • Effective circumvention of drug resistance
  • Innovative and proprietary linker-payload system
  • Broadening the therapeutic window(>10x)
  • Versatile combos aiming for chemo-free frontline